Other formats:
BibTeX
LaTeX
RIS
@article{896289,
author = {Bower, M. and Metzger, T. and Robbins, K. and Tomalty, D. and Válek, Vlastimil and Boudný, Jaroslav and Andrašina, Tomáš and Tatum, C. and Martin, RC.},
article_number = {1},
doi = {http://dx.doi.org/10.1111/j.1477-2574.2009.00117.x},
keywords = {metastatic colon cancer; liver directed therapy; chemoembolization; irinotecan},
language = {eng},
issn = {1365-182X},
journal = {HPB (Oxford)},
title = {Surgical downstaging and neo-adjuvant therapy in metastatic colorectal carcinoma with irinotecan drug-eluting beads: a multi-institutional study},
volume = {12,2010},
year = {2010}
}
TY - JOUR
ID - 896289
AU - Bower, M. - Metzger, T. - Robbins, K. - Tomalty, D. - Válek, Vlastimil - Boudný, Jaroslav - Andrašina, Tomáš - Tatum, C. - Martin, RC.
PY - 2010
TI - Surgical downstaging and neo-adjuvant therapy in metastatic colorectal carcinoma with irinotecan drug-eluting beads: a multi-institutional study
JF - HPB (Oxford)
VL - 12,2010
IS - 1
SP - 31-36
EP - 31-36
SN - 1365182X
KW - metastatic colon cancer
KW - liver directed therapy
KW - chemoembolization
KW - irinotecan
N2 - Background: Neoadjuvant chemotherapy for potentially resectable metastatic colorectal cancer (MCC) is becoming a more common treatment algorithm. The aim of the present study was to evaluate the efficacy of precision hepatic arterial Irinotecan therapy in unresectable MCC. Methods: An open-label, multi-centre, multi-national single arm study of MCC patients, who received hepatic arterial irinotecan. Primary endpoints were safety, tolerance and metastatic tumour resection. Results: Fifty-five patients with metastatic colorectal to the liver underwent a total of 90 hepatic arterial irinotecan treatments. The extent of liver involvement was <25% in 75% of the patients (n = 41), between 26 and 50% in 15% of the patients (n = 11) and >50% in 10% of the patients (n = 24). The median number of hepatic lesions was four (range 1-20), with a median total size of all target lesions of 9 cm (range 5.5-28 cm) with 50% of patients having bilobar tumour distribution. The median number of irinotecan treatments was two (range 1-5). The median treatment dose was 100 mg (range 100-200) with a median total hepatic treatment of 200 mg (range 200-650). The majority of treatments (86%) were performed as lobar infusion treatments, and 30% of patients were treated with concurrent simultaneous chemotherapy. Eleven (20%) patients demonstrated significant response and downstage of their disease or demonstrated stable disease without extra-hepatic disease progression allowing resection, ablation or resection and ablation. There were no post-operative deaths. Post-operative complications morbidity occurred in 18% of patients, with none of them hepatic related. Non-tumorous liver resected demonstrated no evidence of steatohepatitis from the irinotecan arterial infusion. Conclusions: Hepatic arterial infusion irinotecan drug-eluting beads is safe and effective in pre-surgical therapy and helpful in evaluating the biology of metastatic colorectal cancer to the liver prior to planned hepatic resection.
ER -
BOWER, M., T. METZGER, K. ROBBINS, D. TOMALTY, Vlastimil VÁLEK, Jaroslav BOUDNÝ, Tomáš ANDRAŠINA, C. TATUM and RC. MARTIN. Surgical downstaging and neo-adjuvant therapy in metastatic colorectal carcinoma with irinotecan drug-eluting beads: a multi-institutional study. \textit{HPB (Oxford)}. 2010, 12,2010, No~1, p.~31-36, 5 pp. ISSN~1365-182X. Available from: https://dx.doi.org/10.1111/j.1477-2574.2009.00117.x.
|
